KennethShindlerMDPhD
Ophthalmology • Philadelphia, PANeuro-Ophthalmology
Associate Professor of Ophthalmology and Neurology
Dr. Shindler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3801 Filbert St
Philadelphia, PA 19104Phone+1 215-662-8100
Education & Training
University of Pennsylvania Health System/Scheie Eye InstituteResidency, Ophthalmology, 2000 - 2003
Presbyterian Medical Center of the University of Pennsylvania Health SystemInternship, Transitional Year, 1999 - 2000
Washington University in St. Louis School of MedicineClass of 1999
Certifications & Licensure
PA State Medical License 2000 - 2024- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Fellow (FAAO) American Academy of Ophthalmology
Publications & Presentations
PubMed
- Pharmacological Activation and Transgenic Overexpression of SIRT1 Attenuate Traumatic Optic Neuropathy Induced by Blunt Head Impact.Alex Kwok, Brahim Chaqour, Reas S Khan, Puya Aravand, Kimberly Dine
Translational Vision Science & Technology. 2024-09-03 - Corrigendum to "Demyelinating strain of mouse hepatitis virus infection bridging innate and adaptive immune response in the induction of demyelination" [Clinical Immun...Kaushiki Biswas, Dhriti Chatterjee, Sankar Addya, Reas S Khan, Lawrence C Kenyon
Clinical Immunology. 2024-09-01 - 1 citationsComparison of SNCG and NEFH Promoter-Driven Expression of Human SIRT1 Expression in a Mouse Model of Glaucoma.Nuala O'Neill, Miranda Meng, Brahim Chaqour, Kimberly Dine, Neha Sarabu
Translational Vision Science & Technology. 2024-08-01
Other
- RGC Neuroprotection Following Optic Nerve Trauma Mediated by Intranasal Delivery of Amnion Cell SecretomeKenneth Shindler, MD, Investigative Ophthalmology and Visual Science
https://www.doximity.com/articles/b2c40819-4f30-4b0b-b39e-11541972f692
UpToDate, Wolters Kluwer Health - 2012-10-12
Press Mentions
Noveome Biotherapeutics, Inc. Announces Preliminary Results of Its Phase 1 Open Label Clinical Trial Evaluating Intranasal Delivery of Lead Candidate ST266 in Glaucoma Suspect PatientsJune 7th, 2021- Neuroprotection Mediated by ST266 Requires Full Complement of Proteins Secreted by Amnion-Derived Multipotent Progenitor CellsJanuary 6th, 2021
Noveome Biotherapeutics, Inc. Announces Publication of Further Preclinical Results Supporting the Neuroprotective Properties of ST266 in Retinal Ganglion CellsMay 9th, 2019- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
